What is the Fiscal Year for Monopar Therapeutics?
Date: November 13, 2026
Monopar Therapeutics's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Wilmette, Illinois, United States
Industry
Healthcare, Biotechnology Research Services
Stock Symbol
MNPR
Website
https://monopartx.comDescription
Monopar Therapeutics is a clinical-stage biopharmaceutical company developing ALXN1840, a late-stage therapy for Wilson disease, and a radiopharmaceutical pipeline targeting advanced cancers, including MNPR-101-Zr and MNPR-101-Lu in Phase 1 clinical trials and MNPR-101-Ac225 in late preclinical development.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Monopar Therapeutics and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.